A population pharmacokinetic evaluation of the influence of CYP2D6 genotype on risperidone metabolism in patients with acute episode of schizophrenia

European Journal of Pharmaceutical Sciences

Volumn 41, Issue 2, 2010, Pages 289-298

  Locatelli, Igor ^a   Kastelic, Matej ^a   Koprivšek, Jure ^b   Kores Plesničar, Blanka ^c   Mrhar, Aleš ^a   Dolžan, Vita ^a   Grabnar, Iztok ^a  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

^b UNIVERSITY MEDICAL CENTRE MARIBOR   (Slovenia)

^c UNIVERSITY PSYCHIATRIC HOSPITAL   (Slovenia)

Author keywords

9 Hydroxyrisperidone enantiomers; CYP2D6 genotype; Extrapyramidal symptoms; Population pharmacokinetics; Risperidone

Indexed keywords

CYTOCHROME P450 2D6; DRUG METABOLITE; PALIPERIDONE; RISPERIDONE;

ADULT; AGED; ALLELE; ARTICLE; CLINICAL ARTICLE; CREATININE CLEARANCE; DRUG METABOLISM; ENZYME ACTIVITY; FEMALE; GENOTYPE; HUMAN; IN VIVO CULTURE; MALE; PLASMA CLEARANCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCHIZOPHRENIA;

ACUTE DISEASE; ANTIPSYCHOTIC AGENTS; AREA UNDER CURVE; BASE SEQUENCE; BAYES THEOREM; CYTOCHROME P-450 CYP2D6; DNA PRIMERS; GENOTYPE; HUMANS; RISPERIDONE; SCHIZOPHRENIA;

EID: 77955844649     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejps.2010.06.016     Document Type: Article

References (47)

1. Aichhorn W., Weiss U., Marksteiner J., Kemmler G., Walch T., Zernig G., Stelzig-Schoeler R., Stuppaeck C., Geretsegger C. Influence of age and gender on risperidone plasma concentrations. J. Psychopharmacol. 2005, 19:395-401.
2. Balant-Gorgia A.E., Gex-Fabry M., Genet C., Balant L.P. Therapeutic drug monitoring of risperidone using a new, rapid HPLC method: reappraisal of interindividual variability factors. Ther. Drug Monit. 1999, 21:105-115.
3. Bauer L.A. Applied Clinical Pharmacokinetics 2001, McGraw-Hill, New York, pp. 50-55.
4. Beal S.L. Ways to fit a PK model with some data below the quantification limit. J. Pharmacokinet. Pharmacodyn. 2001, 28:481-504.
5. NONMEM User's Guides 1989-2006, Icon Development Solutions, Ellicott City, MD, USA. S.L. Beal, L.B. Sheiner, A. Boeckmann (Eds.).
6. Boom S., Talluri K., Janssens L., Remmerie B., De Meulder M., Rossenu S., van Osselaer N., Eerdekens M., Cleton A. Single- and multiple-dose pharmacokinetics and dose proportionality of the psychotropic agent paliperidone extended release. J. Clin. Pharmacol. 2009, 49:1318-1330.
7. Cleton A., Rossenu S., Vermeulen A., Talluri K., Mertens A., Thyssen A., Janssens L., Boom S. A pharmacokinetic model to document the interconversion between paliperidone enantiomers (conference abstract no. PII-72). Clin. Pharmacol. Ther. 2006, 79:55.
8. de Leon J., Susce M.T., Pan R.M., Wedlund P.J., Orrego M.L., Diaz F.J. A study of genetic (CYP2D6 and ABCB1) and environmental (drug inhibitors and inducers) variables that may influence plasma risperidone levels. Pharmacopsychiatry 2007, 40:93-102.
9. Fang J., Bourin M., Baker G.B. Metabolism of risperidone to 9-hydroxyrisperidone by human cytochromes P450 2D6 and 3A4. Naunyn-Schmied. Arch. Pharmacol. 1999, 359:147-151.
10. Feng Y., Pollock B.G., Coley K., Marder S., Miller D., Kirshner M., Aravagiri M., Schneider L., Bies R.R. Population pharmacokinetic analysis for risperidone using highly sparse sampling measurements from the CATIE study. Br. J. Clin. Pharmacol. 2008, 66:629-639.
11. Hendset M., Molden E., Refsum H., Hermann M. Impact of CYP2D6 genotype on steady-state serum concentrations of risperidone and 9-hydroxyrisperidone in patients using long-acting injectable risperidone. J. Clin. Psychopharmacol. 2009, 29:537-541.
12. Heykants J., Huang M.L., Mannens G., Meuldermans W., Snoeck E., Van Beijsterveldt L., Van Peer A., Woestenborghs R. The pharmacokinetics of risperidone in humans: a summary. J. Clin. Psychiatry 1994, 55 Suppl.:13-17.
13. Hooker A.C., Staatz C.E., Karlsson M.O. Conditional weighted residuals (CWRES): a model diagnostic for the FOCE method. Pharm. Res. 2007, 24:2187-2197.
14. Huang M.L., Van Peer A., Woestenborghs R., De Coster R., Heykants J., Jansen A.A., Zylicz Z., Visscher H.W., Jonkman J.H. Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. Clin. Pharmacol. Ther. 1993, 54:257-268.
15. Jonsson E.N., Karlsson M.O. Xpose--an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput. Methods Programs Biomed. 1999, 58:51-64.
16. Karlsson M.O., Savic R.M. Diagnosing model diagnostics. Clin. Pharmacol. Ther. 2007, 82:17-20.
17. Kim K.A., Park P.W., Liu K.H., Kim K.B., Lee H.J., Shin J.G., Park J.Y. Effect of rifampin, an inducer of CYP3A and P-glycoprotein, on the pharmacokinetics of risperidone. J. Clin. Pharmacol. 2008, 48:66-72.
18. Kores-Plesnicar B.K., Zalar B., Breskvar K., Dolzan V. The influence of the CYP2D6 polymorphism on psychopathological and extrapyramidal symptoms in the patients on long-term antipsychotic treatment. J. Psychopharmacol. 2006, 20:829-833.
19. Lindbom L., Pihlgren P., Jonsson E.N. PsN-Toolkit--a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput. Methods Programs Biomed. 2005, 79:241-257.
20. Llerena A., Berecz R., Dorado P., de la Rubia A. QTc interval, CYP2D6 and CYP2C9 genotypes and risperidone plasma concentrations. J. Psychopharmacol. 2004, 18:189-193.
21. Locatelli I., Mrhar A., Grabnar I. Simultaneous determination of risperidone and 9-hydroxyrisperidone enantiomers in human blood plasma by liquid chromatography with electrochemical detection. J. Pharm. Biomed. Anal. 2009, 50:905-910.
22. Mannens G., Huang M.L., Meuldermans W., Hendrickx J., Woestenborghs R., Heykants J. Absorption, metabolism, and excretion of risperidone in humans. Drug Metab. Dispos. 1993, 21:1134-1141.
23. Mauri M.C., Volonteri L.S., Colasanti A., Fiorentini A., De Gaspari I.F., Bareggi S.R. Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical response. Clin. Pharmacokinet. 2007, 46:359-388.
24. Megens A.A., Awouters F.H., Schotte A., Meert T.F., Dugovic C., Niemegeers C.J., Leysen J.E. Survey on the pharmacodynamics of the new antipsychotic risperidone. Psychopharmacology (Berl.) 1994, 114:9-23.
25. Mihara K., Kondo T., Yasui-Furukori N., Suzuki A., Ishida M., Ono S., Kubota T., Iga T., Takarada Y., de Vries R., Kaneko S. Effects of various CYP2D6 genotypes on the steady-state plasma concentrations of risperidone and its active metabolite, 9-hydroxyrisperidone, in Japanese patients with schizophrenia. Ther. Drug Monit. 2003, 25:287-293.
26. Miller S.A., Dykes D.D., Polesky H.F. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988, 16:1215.
27. Odou P., Levron J., Luyckx M., Brunet C., Robert H. Risperidone drug monitoring: a useful clinical tool?. Clin. Drug Invest. 2000, 19:283-292.
28. Ono S., Mihara K., Suzuki A., Kondo T., Yasui-Furukori N., Furukori H., de Vries R., Kaneko S. Significant pharmacokinetic interaction between risperidone and carbamazepine: its relationship with CYP2D6 genotypes. Psychopharmacology (Berl.) 2002, 162:50-54.
29. Raimundo S., Toscano C., Klein K., Fischer J., Griese E.U., Eichelbaum M., Schwab M., Zanger U.M. A novel intronic mutation, 2988G>A, with high predictivity for impaired function of cytochrome P450 2D6 in white subjects. Clin. Pharmacol. Ther. 2004, 76:128-138.
30. Riedel M., Schwarz M.J., Strassnig M., Spellmann I., Muller-Arends A., Weber K., Zach J., Muller N., Moller H.J. Risperidone plasma levels, clinical response and side-effects. Eur. Arch. Psychiatry Clin. Neurosci. 2005, 255:261-268.
31. Roh H.K., Kim C.E., Chung W.G., Park C.S., Svensson J.O., Bertilsson L. Risperidone metabolism in relation to CYP2D6*10 allele in Korean schizophrenic patients. Eur. J. Clin. Pharmacol. 2001, 57:671-675.
32. Savic R.M., Karlsson M.O. Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions. AAPS J. 2009, 11:558-569.
33. Scordo M.G., Spina E., Facciola G., Avenoso A., Johansson I., Dahl M.L. Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone. Psychopharmacology (Berl.) 1999, 147:300-305.
34. Silber H.E., Kjellsson M.C., Karlsson M.O. The impact of misspecification of residual error or correlation structure on the type I error rate for covariate inclusion. J. Pharmacokinet. Pharmacodyn. 2009, 36:81-99.
35. Simpson G.M., Lindenmayer J.P. Extrapyramidal symptoms in patients treated with risperidone. J. Clin. Psychopharmacol. 1997, 17:194-201.
36. Snoeck E., Van Peer A., Sack M., Horton M., Mannens G., Woestenborghs R., Meibach R., Heykants J. Influence of age, renal and liver impairment on the pharmacokinetics of risperidone in man. Psychopharmacology (Berl.) 1995, 122:223-229.
37. Spina E., Avenoso A., Facciola G., Salemi M., Scordo M.G., Giacobello T., Madia A.G., Perucca E. Plasma concentrations of risperidone and 9-hydroxyrisperidone: effect of comedication with carbamazepine or valproate. Ther. Drug Monit. 2000, 22:481-485.
38. Spina E., Avenoso A., Facciola G., Salemi M., Scordo M.G., Ancione M., Madia A.G., Perucca E. Relationship between plasma risperidone and 9-hydroxyrisperidone concentrations and clinical response in patients with schizophrenia. Psychopharmacology (Berl.) 2001, 153:238-243.
39. Vermeir M., Naessens I., Remmerie B., Mannens G., Hendrickx J., Sterkens P., Talluri K., Boom S., Eerdekens M., van Osselaer N., Cleton A. Absorption, metabolism, and excretion of paliperidone, a new monoaminergic antagonist, in humans. Drug Metab. Dispos. 2008, 36:769-779.
40. Vermeulen A., Piotrovsky V., Ludwig E.A. Population pharmacokinetics of risperidone and 9-hydroxyrisperidone in patients with acute episodes associated with bipolar I disorder. J. Pharmacokinet. Pharmacodyn. 2007, 34:183-206.
41. Wang L., Yu L., Zhang A.P., Fang C., Du J., Gu N.F., Qin S.Y., Feng G.Y., Li X.W., Xing Q.H., He L. Serum prolactin levels, plasma risperidone levels, polymorphism of cytochrome P450 2D6 and clinical response in patients with schizophrenia. J. Psychopharmacol. 2007, 21:837-842.
42. Yang L.P., Plosker G.L. Paliperidone extended release. CNS Drugs 2007, 21:417-425. (discussion 426-417).
43. Yasui-Furukori N., Hidestrand M., Spina E., Facciola G., Scordo M.G., Tybring G. Different enantioselective 9-hydroxylation of risperidone by the two human CYP2D6 and CYP3A4 enzymes. Drug Metab. Dispos. 2001, 29:1263-1268.
44. Yasui-Furukori N., Mihara K., Kondo T., Kubota T., Iga T., Takarada Y., De Vries R., Kaneko S., Tateishi T. Effects of CYP2D6 genotypes on plasma concentrations of risperidone and enantiomers of 9-hydroxyrisperidone in Japanese patients with schizophrenia. J. Clin. Pharmacol. 2003, 43:122-127.
45. Yasui-Furukori N., Saito M., Nakagami T., Furukori H., Suzuki A., Kondo T., Kaneko S. Clinical response to risperidone in relation to plasma drug concentrations in acutely exacerbated schizophrenic patients. J. Psychopharmacol. 2010, 24:987-994.
46. Yoshimura R., Ueda N., Nakamura J. Possible relationship between combined plasma concentrations of risperidone plus 9-hydroxyrisperidone and extrapyramidal symptoms. Preliminary study. Neuropsychobiology 2001, 44:129-133.
47. Zanger U.M., Raimundo S., Eichelbaum M. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn-Schmied. Arch. Pharmacol. 2004, 369:23-37.